Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A  by Strotmeier, Jasmin et al.
FEBS Letters 588 (2014) 1087–1093journal homepage: www.FEBSLetters .orgIdentiﬁcation of the synaptic vesicle glycoprotein 2 receptor binding site
in botulinum neurotoxin Ahttp://dx.doi.org/10.1016/j.febslet.2014.02.034
0014-5793/ 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
Abbreviations: BoNT, botulinum neurotoxin; GBS, ganglioside binding site; GST,
glutathion-S-transferase; HC, heavy chain; HC, carboxyl-terminal half of HC; HCA,
HCE, HCF, HCG, HCX, HC fragment of BoNT serotype A, E, F, G or A-G respectively; HN,
amino-terminal half of HC; H6F3HCXS, N-terminal 6 His tag, 3 Flag tag, HC
fragment of serotype A-G, C-terminal Streptag; LC, light chain; mAb, monoclonal
antibody; MPN assay, mice phrenic nerve hemidiaphragm assay; scFv, single-chain
variable fragments; rSV2A, B, C, rat synaptic vesicle glycoprotein 2 isoform A, B, or
C; Syt, synaptotagmin; CD, circular dichroism
⇑ Corresponding author. Fax: +49 511 532 8021.
E-mail address: Rummel.Andreas@mh-hannover.de (A. Rummel).Jasmin Strotmeier a, Stefan Mahrhold a,b, Nadja Krez a, Constantin Janzen a, Jianlong Lou c,
James D. Marks c, Thomas Binz b, Andreas Rummel a,⇑
a Institut für Toxikologie, OE 5340, Medizinische Hochschule Hannover, 30623 Hannover, Germany
b Institut für Biochemie, OE 4310, Medizinische Hochschule Hannover, 30623 Hannover, Germany
cDepartment of Anesthesia, University of California, San Francisco, CA 94110, USAa r t i c l e i n f o
Article history:
Received 8 January 2014
Revised 4 February 2014
Accepted 4 February 2014
Available online 25 February 2014
Edited by Maurice Montal
Keywords:
Botulinum neurotoxin A
Protein receptor binding site
SV2
Monoclonal antibody
Neutralisationa b s t r a c t
Botulinum neurotoxins (BoNTs) inhibit neurotransmitter release by hydrolysing SNARE proteins.
The most important serotype BoNT/A employs the synaptic vesicle glycoprotein 2 (SV2) isoforms
A-C as neuronal receptors. Here, we identiﬁed their binding site by blocking SV2 interaction using
monoclonal antibodies with characterised epitopes within the cell binding domain (HC). The site
is located on the backside of the conserved ganglioside binding pocket at the interface of the
HCC and HCN subdomains. The dimension of the binding pocket was characterised in detail by site
directed mutagenesis allowing the development of potent inhibitors as well as modifying receptor
binding properties.
Structured summary of protein interactions:
HCA binds to rSV2A by pull down (View interaction)
BoNT/A binds to rSV2C by pull down (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
HCA physically interacts with SV2A and SV2B by anti tag coimmunoprecipitation (View interaction)
HCE physically interacts with SV2A and SV2B by anti tag coimmunoprecipitation (View interaction)
HCF physically interacts with SV2A and SV2B by anti tag coimmunoprecipitation (View interaction)
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The fatal disease botulism, a ﬂaccid paralysis of the muscles, is
caused by blockade of the acetylcholine release at the neuromus-
cular junction due to intoxication with botulinum neurotoxins
(BoNTs) even at minute quantities. On the other hand, of the seven
major serotypes A-G the serotype BoNT/A constitutes a highly
effective, widespread medicine to treat diseases like cervical
dystonia, blepharospasm, hyperhidrosis and overactive bladdersyndrome. All BoNTs are composed of four functional domains
which play individual roles in their intoxication mechanism. The
N-terminal 50 kDa light chain (LC) proteolyses speciﬁcally a mem-
ber of the soluble N-ethlymaleimide sensitive attachment protein
receptors family of proteins which are part of the vesicular fusion
machinery [1,2]. The C-terminal 100 kDa heavy chain (HC) consists
of three domains. Juxtaposed to LC is the 50 kDa a-helical translo-
cation domain, the amino-terminal half of HC (HN), and the
remaining 50 kDa HC-fragment comprises the HCN domain which
might trigger the translocation step [3] and the HCC domain
which harbours the binding sites for gangliosides and in case of
BoNT/B, DC, and G for the synaptic vesicle (SV) protein receptor
synaptotagmin [4].
BoNTs are taken up by neurons via a double receptor mecha-
nism [5–7]. First, neuron speciﬁc abundant polysialo gangliosides
like GT1b, GD1a and GD1b enrich BoNTs on the plasma membrane
to facilitate contact with the intravesicular parts of the transiently
occurring SV protein receptors [8]. E.g., BoNT/B, DC and G bind the
membrane neighbouring 15–17 amino acids of the intraluminal
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tagmin (Syt)-I and Syt-II in the distal tip of their HC-fragment (Syt
site) in the direct neighbourhood of the conserved ganglioside
binding pocket in different arrangements [6,9–16].
Later, the large intravesicular domain 4 (LD4) of the synaptic
vesicle glycoprotein 2 (SV2) isoforms A–C was discovered as recep-
tor domains for BoNT/A [17,18], the unglycosylated, isolated LD4 of
SV2C exhibiting the highest afﬁnity to BoNT/A HC. However, since
all three SV2 isoforms are expressed in a-motoneurons [17], it is
still not clear which SV2 isoform is most relevant for the physiolog-
ical uptake of BoNT/A.
In contrast to BoNT/A, functional studies revealed that BoNT/E
only interacts with SV2A and SV2B, but not with SV2C [19] while
the biological activity of BoNT/D primarily requires the presence
of SV2B and to a lesser extent of SV2A and C [20]. However, a direct
protein–protein interaction between SV2 and BoNT/D remains to
be shown like for BoNT/F which co-precipitated SV2A-C from rat
brain synaptic vesicle lysates [21,22]. Altogether, BoNT/A, D, E
and F utilise seemingly diverse SV2-binding mechanisms.
Only recently, the ﬁrst SV2 binding pocket could be mapped in
BoNT/E to an extended surface area located on the back of the con-
served ganglioside binding site comprising the HCN and HCC inter-
face, part of the corresponding Syt site in BoNT/B and the region in
between (ODA1 site), the latter two also constituting a partial epi-
tope of the monoclonal antibody (mAb) 4E13 which neutralises
BoNT/E activity [23]. The SV2A binding site in BoNT/E seems to
represent the prototypic region for all other BoNTs that exploit
SV2 as a cell surface receptor. In accordance, a co-crystal structure
allocated the binding site of human SV2C in BoNT/A to the HCN and
HCC interface adjacent to the SV2A binding site in BoNT/E [24].
Here, we identiﬁed the SV2 binding site at the interface of HCC
and HCN domains of BoNT/A employing neutralising mAbs with de-
ﬁned epitopes used as therapeutics [25]. Site-directed mutagenesis
characterised the SV2 binding pocket in detail and exhibited the
single mutation G1292R decreasing the biological activity of
BoNT/A 300-fold. Employment of ganglioside deﬁcient mice and
BoNT/A mutants comprising deactivated receptor binding sites
proved that the double receptor model also accounts for BoNT/A.2. Materials and methods
Anti-BoNT/A mAb CR2 and scFvs RAZ1, S25 and CR2 were gen-
erated as described previously [25–29]. Fig. 1B was prepared using
the program Discovery Studio Visualizer 2.5 (Accelrys Software
Inc.) based on 2NYY.pdb [28].
2.1. Plasmid constructions and production of proteins
Rat GST-rSV2C 454–579 encoded by pGEXrSV2C 454–579 and
rat GST-rSV2A 468–594 encoded by pGEXrSV2A 468–594 were
produced as described previously [18]. The plasmid pH6tBoNTA1
encoding BoNT/A1 fused to an N-terminal His6tag was generated
by modifying pBoNTAS [30]. The plasmids pHCAS, pH6F3HCES
and pH6F3HCGS were described previously [15,23,30], pH6F3HCES
serving as parental vector for pH6F3HCAS and pH6F3HCFS which
were generated by ligation of DNA sequences encoding HCA (aa
871–1296) from pS3HCAH6 and HCF (aa 866–1277) from pS3HC-
FH6 [22]. All pH6tBoNTA1 and pH6F3HCAS mutants were prepared
using the GeneTailor method (Invitrogen GmbH, Karlsruhe, Ger-
many) employing suitable primers and pH6tBoNTA1 and pH6F3HC-
AS, respectively, as template DNA. Nucleotide sequences of all
mutants were veriﬁed by DNA sequencing.
Wild-type and mutated recombinant H6F3HCXS (= N-terminal
6 His tag, 3 Flag tag, HC fragment of serotype A-G, C-terminal
Streptag), HCAS and full-length neurotoxins, the latter underbiosafety level 2 containment (project number GAA A/Z 40654/3/
123), were produced utilising the Escherichia coli strain M15pREP4
(Qiagen, Germany) during 16 h of induction at 22 C in the pres-
ence of 0.2 mM IPTG, and were puriﬁed on Co2+-Talon matrix
(Takara Bio Europe S.A.S., France). Full-length neurotoxins were
eluted using 50 mM Tris–HCl, pH 8.0, 150 mM NaCl, 250 mM imid-
azole, subjected to gel ﬁltration (Superdex-200 16/60 column, GE
Healthcare, Germany) in 100 mM Tris–HCl, pH 8.0, 150 mM NaCl,
frozen in liquid nitrogen and kept at 70 C. H6F3HcXS proteins
were eluted using 100 mM Tris–HCl pH 8.0, 150 mM NaCl,
100 mM Imidazole and further puriﬁed on StrepTactin-Sepharose
beads (IBA GmbH, Germany). Proteins were eluted by 10 mM des-
thiobiotin in 100 mM Tris–HCl pH 8.0, 150 mM NaCl, frozen in li-
quid nitrogen and kept at 70 C. For circular dichroism (CD)
analysis desired volume of protein was dialysed against 1 PBS
pH 7.4.
Protein concentrations were determined subsequent to SDS–
PAGE and Coomassie blue staining by using a LAS-3000 imaging
system (Fuji Photo Film), the AIDA 3.51 program, and various
known concentrations of BSA as reference.
2.2. GST-pull down assays
For competition experiments HCAS (100 pmol) or H6tBoNTA
(50 pmol) were preincubated with mAb (400 pmol) for 30 min at
RT in 187.5 ll in 100 mM Tris–HCl, pH 8.0, 150 mM NaCl.
Glutathion-S-transferase (GST, 150/75 pmol), GST-rSV2A 468–
594 (150 pmol) and GST-rSV2C 454–579 (75 pmol) immobilised
to 10 ll of glutathione-Sepharose-4B matrix (GE healthcare, Ger-
many) were incubated with HCAS (100 pmol), H6tBoNTA wild-type
(with or without preincubated mAbs) or mutants (50 pmol each) in
a total volume of 200 ll 100 mM Tris–HCl, pH 8.0, 150 mM
NaCl, supplemented with 0.5% Triton X-100 (Tris/NaCl/Triton) buf-
fer for 2 h at 4 C. Beads were collected by centrifugation and
washed two times each with 200 ll Tris/NaCl/Triton buffer.
Washed pellet fractions were denatured in SDS sample buffer for
20 min at 37 C and analysed by SDS–PAGE. Proteins were detected
by Coomassie blue staining and subsequently quantiﬁed by
densitometry.
2.3. Mouse phrenic nerve hemidiaphragm (MPN) assay
The mice phrenic nerve hemidiaphragm assay (MPN assay) was
performed as described previously employing 20–30 g NMRI mice
(Janvier SA, France) [31] or complex polysialo ganglioside deﬁcient
C57BL/6 mice lacking the genes B4galnt1 and/or St8sia1 [22]. The
phrenic nerve was continuously stimulated at 5–25 mA with a fre-
quency of 1 Hz and with a 0.1 ms pulse duration. Isometric con-
tractions were transformed using a force transducer and
recorded with VitroDat Online software (FMI GmbH, Germany).
The time required to decrease the amplitude to 50% of the starting
value (paralytic half-time) was determined. To allow comparison
of the altered neurotoxicity of mutants with H6tBoNTA wild-type,
a power function (y(H6tBoNTA; 10, 30, 80 pM) = 139.6x0.1957,
R2 = 0.9991) was ﬁtted to a concentration–response-curve consist-
ing of three concentrations determined minimum in triplicates.
Resulting paralytic half-times of the H6tBoNTA mutants were con-
verted to concentrations of the wild-type employing the above
power functions and ﬁnally expressed as relative neurotoxicity
(Figs. 3 and 5).
2.4. Co-immunoprecipitation
All centrifugation and incubation steps were carried out at 4 C,
except where otherwise stated. The preparation of rat brain
synaptosomes was performed as previously described [31].
Fig. 1. (A) Binding of full-length BoNT/A to GST-rSV2C 454–579 is blocked by monoclonal antibody IgG CR2 and its corresponding scFv. H6tBoNTA (50 pmol) serving as prey
was preincubated with mAb (400 pmol) for 30 min at RT (‘‘input’’) in 200 ll 100 mM Tris–HCl, pH 8.0, 150 mM NaCl, 0.5% Triton X-100 and subsequently incubated for 2 h at
4 C with the bait, immobilised GST-rSV2C 454–579 (75 pmol). Bound H6tBoNTA was detected by 12.5% SDS–PAGE analysis and Coomassie blue staining. (B) Complex crystal
structure of BoNT/A HC (HCC, light gray surface; HCN, dark grey surface) and the variable part of CR1 Fab (orange ribbon; modiﬁed from 2NYY.pdb). Residues in the analogous
Syt site/RAZ1 epitope are depicted in green, those of the ODA1 site in light blue or dark blue (effect on SV2C binding). All positions analysed in the CR2 site are coloured in
orange, those with clear effect on SV2C binding in red.
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7.4, 80 mM NaCl, 0.5% Triton X-100) for 1 h, subsequently centri-
fuged at 21,000g for 10 min and the supernatant was transferred
into a fresh tube. Co-immunoprecipitation of native SV2A and B
was done in lysis buffer supplemented with 0.1% BSA in a total vol-
ume of 200 ll employing 10 ll Protein G agarose beads (Amer-
sham Biosciences), 6 lg of anti-Flag M2 monoclonal antibody
(Sigma–Aldrich), 12 lg of the indicated BoNT HC-fragment and50 lg of synaptosomal proteins in the presence of 125 lg mixed
bovine brain gangliosides for 3 h. Thereafter, beads were collected
by centrifugation at 2000g and washed three times using lysis
buffer. Washed pellet fractions were incubated in Laemmli sample
buffer for 20 min at 37 C and analysed by SDS–PAGE and Western
blotting (rabbit polyclonal anti-SV2A & anti-SV2B, Synaptic Sys-
tems, Germany; goat anti-rabbit, Pierce; StrepMAP Classic-HRP,
IBA GmbH, Germany).
Fig. 2. Binding of H6tBoNTA single mutants (50 pmol) for 2 h at 4 C to immobilised GST-rSV2C 454–579 (75 pmol) in 200 ll 100 mM Tris–HCl, pH 8.0, 150 mM NaCl, 0.5%
Triton X-100. Bound H6tBoNTA mutants were detected by 10% SDS–PAGE analysis and Coomassie blue staining (wt n = 15, mutants n = 3–5, ±SD), quantiﬁed by densitometry
and compared versus wild-type binding.
Fig. 3. The impact of mutations on the neurotoxicity of BoNT/A was analysed employing MPN preparations. The paralytic halftimes were determined and converted to the
corresponding concentrations of wild-type BoNT/A using a concentration–response curve. The resulting toxicities were ﬁnally expressed relative to wild-type BoNT/A (n = 3–
5, ±SD).
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The HC-fragment of BoNT/A displays the highest afﬁnity to the
luminal domain 4 (residues 454–579) of the isoform SV2C inde-
pendent of its glycosylation status followed by SV2A and SV2B
[17,18]. This direct protein–protein interaction is clearly demon-
strated in a GST pull down assay employing full-length recombi-
nant H6tBoNTA and rat GST-rSV2C 454–579 (Fig. 1A). The
weaker binding of HCA to recombinant rat GST-rSV2A 468–594 is
also shown (Fig. S1) whereas binding to non-glycosylated rSV2B
is hardly detectable. Well characterised neutralising monoclonalantibodies directed against different epitopes within the HC-frag-
ment of BoNT/A [25–29] were screened for interference with the
SV2C interaction. To avoid putative cross-linking of two BoNT/A
molecules by an intact IgG which could impair SV2 binding, we ini-
tially pre-incubated H6tBoNTA with the single-chain variable frag-
ments (scFv) S25, RAZ1 and CR2 in 8-fold excess. scFv S25 is
directed against residues 1254–56 forming a part of the rim of
the single ganglioside binding site (GBS) [30]; RAZ1 is an afﬁnity
matured mAb based on 3D12 directed against residues 1129–31
comprising the region analogous to the Syt binding site in BoNT/
B and G [6,14]. CR2 and the closely related CR1 are engineered
Fig. 4. Co-immunoprecipitation of SV2A and B by selected HCA mutants was
performed by incubating 12 lg of 3  Flag-tagged wild-type and mutant H6F3HCAS,
H6F3HCES, H6F3HCFS and H6F3HCGS with 6 lg anti-Flag-tag M2 antibody and
Triton X-100 solubilised rat brain synaptosomal membranes. Bound SV2A and B
were detected by Western blotting, amount of precipitated H6F3HCXS was veriﬁed
by HRP conjugated StrepMAB classic. MWM denotes molecular weight marker.
Fig. 5. The neurotoxicity of wild-type and BoNT/A mutants either with inactivated
GBS (W1266L), inactivated SV2 binding site (R1156M, G1292R) or both was
determined employing wild-type and ganglioside-deﬁcient tissue for the MPN
assay (n = 7–16, ±SD).
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918–20, F953 and 1062–64 at the interface of the HCC and HCN do-
main [28,29] (Fig. 1B). Whereas scFv S25 did not and RAZ1 only
marginally altered the interaction of GST-rSV2C with H6tBoNTA,
the scFv CR2 eliminated the precipitation of H6tBoNTA by
GST-rSV2C (Fig. 1A). Analogously, the 48-fold excess of IgG CR2
terminated binding of H6tBoNTA to GST-rSV2C, which explainsits potency in ex vivo MPN assay as well as in in vivo mice toxin
neutralisation assays [26]. Hence, a main interaction site of SV2C
with BoNT/A resides in the epitope region of CR2. Analogously,
CR2 was able to inhibit the precipitation of HCA by GST-rSV2A
LD4 (468–594) indicating that both SV2 isoforms interact with
the same surface area of BoNT/A (Fig. S1). Previously, the CR2 epi-
tope was mapped in detail by two crystal structure complexes con-
sisting of BoNT/A and Fabs of CR1 or AR2, respectively, closely
related mAbs recognising identical epitopes [28] (Fig. 1B). Based
on this structural data site directed mutagenesis was performed
in the CR2 site, the Syt/RAZ1 site as well as in the region connect-
ing both surface areas called ODA1 site according to Mahrhold
et al. [23].
The full-length recombinant H6tBoNTA mutants were screened
in pull down assays employing rat GST-rSV2C 454–579. Charge
reversal by R1131E in the RAZ1 site and K1163E in the ODA1 site
decreased precipitation of H6tBoNTA, even more pronounced for
mutation N1188A in the ODA1 site (Fig. 2). Furthermore, 15 muta-
tions in the CR2 site were generated. Here, the H6tBoNTA single
mutants N905Y, T1063P, H1064G, D1108R, R1156M, V1287E and
G1292R displayed a 50% or greater decrease of binding to GST-
rSV2C which is in good agreement with binding assay data ob-
tained for the CR2-related humanised C25 [29] and the crystallised
complexes BoNT/A-CR1 or AR2 which identiﬁed i.a. T1063 and
H1064 as key residues in their epitopes [28]. With the exception
of D1124R also the remaining seven mutants showed at least mod-
erately reduced afﬁnity to GST-rSV2C (Fig. 2).
To verify whether the reduced afﬁnity of the BoNT/A mutants to
recombinant rSV2C LD4 also translates into reduced biological
activity all 21 mutants were tested in the MPN assay. Correspond-
ingly, mutants H6tBoNTA R1131E and K1260E in the RAZ1 site and
N1188A within the ODA1 site showed diminished potency (Fig. 3).
Also mutations N905Y, F917A, T1063P, H1064G, D1108R, P1110W,
D1124R, R1156M, V1287E and D1289G/R in the CR2 site caused a
decrease of more than 50% in neurotoxicity. The single mutant
G1292R even displayed a 300-fold reduction in potency. Thus the
MPN data largely conﬁrms the previous in vitro binding data ob-
tained with isolated rat GST-rSV2C 454–579, also because the LD4
of mouse and rat SV2C differ only in three conservative amino acid
exchanges. Noteworthy, the isoforms SV2A and B are also expressed
in motoneurons [17], although neither their differential expression
levels nor their afﬁnity to BoNT/A have been quantiﬁed. The amino
acid sequence identity between the LD4 of rSV2A, rSV2B and rSV2C
is only 48% and 44%, respectively. Hence, differences between the
GST-rSV2C pull down and the MPN assay as observed for mutants
P1110W, D1124R and D1289G/R could be explained by subtle dif-
ferences in the mode of interaction of the three SV2 isoforms. In
conclusion, the main SV2C binding site is allocated in the CR2 epi-
tope site at the interface of HCC and HCN domains on the backside of
the GBS extending towards the Syt/RAZ1 binding site. Our ﬁnding is
in good agreement with a recently published co-crystal structure of
human SV2C residues 456–579 bound to the BoNT/A HC-fragment
where one b-strand of the SV2C quadrilateral b-helix interacts with
the convex b-sheet (1140-56) at the BoNT/A HCC-HCN interface [24].
This b-sheet is adjacent to the CR2 epitope in HCN-HCC. Here, T1145/
46 and R1156 dominate the few proposed side chain-side chain
interactions. Analogously, our mutant R1156M showed the lowest
afﬁnity to GST-rSV2C. Secondly, the strong effects observed for
mutation of G1292 is in accordance with data of Benoit et al. show-
ing impaired hSV2C interaction upon mutation of the neighbouring
R1294 to alanine [24]. Furthermore, comparison with the SV2A-
binding site in BoNT/E shows that mutation of Y879, E1246 and
K1084 in BoNT/E, like the corresponding residues N905, V1287
and D1108 in BoNT/A for SV2C, interferes with SV2A-binding of
BoNT/E. This illustrates that the SV2 binding site of BoNT/A covers
the homologous region of BoNT/E [23].
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did not impair its structural integrity and thereby caused the loss
in SV2C binding, the mutations displaying the most severe effects
(R1156M, V1287E and G1292R) were transferred into HC-frag-
ments fused to an N-terminal 3  FLAG tag. The thermal stability
of the HC-fragment mutants was virtually identical to the wild-
type (51 ± 1 C; Fig. S2) indicating that the secondary structure
was not altered due to the single amino acid exchanges.
To further deepen the conclusion obtained for the interaction
site of SV2 in BoNT/A, co-immunoprecipitation experiments were
conducted employing 3  FLAG tagged BoNT/A HC-fragment mu-
tants (H6F3HCAS; Fig. 4). Since the tissue from motoneurons as
physiological target cannot be accessed in sufﬁcient quantities, rat
brain synaptosomes were generated and solubilised in Triton X-
100. However, whereas SV2A is ubiquitously expressed in virtually
all synapses and SV2B was also found in a wide variety of synapses
throughout the brain, SV2C was observed only in few brain areas
like the pallidum, the substantia nigra, the midbrain, the brainstem
and the olfactory bulb, but was undetectable in the cerebral cortex
and the hippocampus, and found at low levels in the cerebellar cor-
tex [32]. Hence, SV2C constitutes only a minor fraction in synapto-
somal lysates and HCA wild-type co-precipitated only minor
amounts. In contrast, SV2A and SV2B were satisfactorily precipi-
tated by HCA wild-type (Fig. 4). HCA mutants R1156M and V1287E
showed similar afﬁnity to SV2A and SV2B as wild-type HCA indicat-
ing subtle differences between the mode of interaction of SV2A/B
and of SV2C with BoNT/A. R1156 is suggested to interact with
F563 of human SV2C by cation–p-stacking interaction [24]. How-
ever, mouse and rat SV2C comprise L563 which does not allow this
cation–p-stacking, but possibly R1156 establishes a salt bridge to
the neighbouring E543 in rat SV2C. However, the corresponding res-
idues Y557 in rSV2A and Y500 in SV2Bwould form aweakerH-bond
to R1156. Consequently, mutant R1156M does only moderately
interfere with SV2A and B binding. The lack of effect for mutant
V1287E cannot be deduced from the HCA-hSV2C complex structure.
In contrast,mutantHCAG1292Rdid neither co-precipitate SV2Anor
SV2Bwhich conﬁrms the conclusion that also SV2A and SV2B inter-
act at the similar region on theHCA surface. Hereby, the strong effect
of mutation G1292R on SV2A-C interaction also explains the drastic
decrease of biological activity of H6tBoNTA G1292R in the MPN as-
say compared to all other mutants in the CR2 site.
The single BoNT/A mutant G1292R with eliminated SV2 protein
receptor recognition, the mutant W1266L lacking ganglioside
binding [30] as well as ganglioside deﬁcient mice [33] provided
powerful tools to prove the dual receptor hypothesis for BoNT/A
analogously to BoNT/B and G [6]. Like previously shown [22], the
sensitivity of tissue expressing GM3 only was decreased by
600-fold for wild-type H6tBoNTA (Fig. 5) which corresponds to
the decrease in sensitivity of wild-type mice hemidiaphragm tissue
towards H6tBoNTAW1266L bearing a deactivated GBS [30] (Fig. 5).
Whereas the neurotoxicity of the mutant W1266L at GM3-only tis-
sue remained roughly the same, the H6tBoNTA G1292R with inac-
tivated SV2 binding site (= 300-fold reduced neurotoxicity at wild-
type tissue) showed further reduced neurotoxicity at ganglioside-
deﬁcient tissue indicating the importance of both receptor interac-
tions (Fig. 5). Finally, the double mutant comprising W1266L and
G1292R turning both receptor sites inactive displayed a 250,000-
fold reduced biological activity in the MPN assay (Fig. 5). In com-
parison, the individual mutations each decreased the potency by
200- and 300-fold demonstrating the synergy of both binding
sites for the intoxication mechanism.
In conclusion, exchange of two critical amino acids in the GBS
and the newly identiﬁed SV2 binding site generates a virtually
atoxic BoNT/A which adds another piece of evidence for the dual
receptor mechanism by which botulinum neurotoxins speciﬁcally
enter nerve cells [4,5]. Furthermore, the knowledge of both recep-tor binding sites now allows the design of bivalent inhibitor mole-
cules blocking the uptake of BoNT/A in case of its deliberate or
accidental release. Also the retargeting of BoNT/A to e.g. non-neu-
ronal cells to treat diseases caused by overactive secretion mecha-
nisms which has so far been achieved by replacing the whole HC-
fragment [34] could now be accomplished with minimal altera-
tions in the SV2 binding site. And in combination with three critical
substitutions in the LC interfering with the catalytic mechanism
[35–37] such a quintuple mutant represents an ideal atoxic antigen
to generate vaccines against physiologically folded BoNT/A.Acknowledgements
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